HIV Scientific Papers

Virologic effectiveness of ibalizumab clinical trial experience compared to real-world clinical care without ibalizumab in the OPERA® Cohort
Laurence Brunet, Michele L. Jonsson Funk, R Brandon Cash, Jennifer S. Fusco, Lydia Walder, Andrew Laws, Michael Wohlfeiler, Michael Sension, Gregory P. Fusco
Achieving virological control in pan-resistant HIV-1 infection: A case series
Diana Canetti, Camilla Muccini, Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Nicola Gianotti, Marcello Feasi, and Antonella Castagna,
The Lancet Vol 77 Month March, 2022 11
IV Push Administration of Ibalizumab: Pharmacokinetics, Safety, and Efficacy
Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Anthony Mills, Tanya Schreibman, Charlotte-Paige Rolle, Kuei-Ling Kuo, Mohammed Zogheib, Olivia G. Goss, R. Brandon Cash, YingAn Lai, Martin Markowitz, Pedro M. Mesquita 
HIV-1 Non-Group M Phenotypic Susceptibility to Ibalizumab
L. Poisson-Arnaud, Quentin le Hingrat, JC Plantier and E Alessandri-Gradt
Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study.
J Acquir Immune Defic Syndr.
Gathe JC, Hardwicke RL, Garcia F, et al.